Andrew J. Fletcher, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editors: Roeback and colleagues (1) provide an elegant pharmacologic demonstration of the different effects of two drugs on high-density lipoprotein (HDL) cholesterol levels in men, but I take issue with certain of their premises and conclusions.
First, the authors refer to their expectation that "reducing hypertension, an acknowledged risk factor for coronary heart disease, should decrease mortality and morbidity from coronary heart disease." One of the curiosities of hypertension
observed many years ago was that the antihypertensive agents then in use reduced the incidence of heart failure, renal failure, and stroke, but not that of coronary heart disease
Fletcher AJ. Chromium and High-Density Lipoprotein Levels in Men Taking Beta-Blockers. Ann Intern Med. 1992;117:91–93. doi: https://doi.org/10.7326/0003-4819-117-1-91_2
Download citation file:
Published: Ann Intern Med. 1992;117(1):91-93.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use